

Prevalence Of Antibiotic Resistance Patterns In Clinical Isolates From Hospital Laboratories

Mohammed yahya taha alqahtani¹, Ahmed ali barakat alkinani², Yahya Haris Yahya Alzahrani³, Faisal Musareb al Ghamdi⁴, Mohamed Darrag hamed algaidi⁵, Fakreha Ahmed Eissa Kordi⁶, Bandar Rafee Said Alsolami⁷, Majed Mohammed Ahmed Oreijah⁸

¹.Ministry of Health, Saudi Arabia

².Ministry of Health, Saudi Arabia

³.Ministry of Health, Saudi Arabia

⁴.Ministry of Health, Saudi Arabia

⁵.Ministry of Health, Saudi Arabia

⁶.Ministry of Health, Saudi Arabia

⁷.Ministry of Health, Saudi Arabia

⁸.Ministry of Health, Saudi Arabia

Abstract

Antibiotic resistance has emerged as one of the most critical global public health challenges, threatening the effective prevention and treatment of a wide range of infectious diseases. The increasing prevalence of resistant pathogens in hospital settings significantly complicates clinical management, prolongs hospital stays, raises healthcare costs, and increases morbidity and mortality rates. This research paper investigates the prevalence and distribution of antibiotic resistance patterns among clinical isolates obtained from hospital laboratories. The study focuses on commonly isolated bacterial pathogens from various clinical samples, including blood, urine, sputum, pus, and wound swabs. Standard microbiological techniques were employed for isolation and identification of bacterial strains, followed by antimicrobial susceptibility testing using the Kirby–Bauer disk diffusion method in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. The findings reveal a high prevalence of multidrug-resistant organisms, particularly among *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. Resistance to commonly prescribed antibiotics such as penicillins, cephalosporins, and fluoroquinolones was notably high, while comparatively lower resistance was observed against carbapenems and glycopeptides. The study underscores the urgent need for continuous surveillance of antimicrobial resistance, rational antibiotic prescribing practices, and strengthened infection control measures within hospital environments. The outcomes of this research contribute valuable insights for clinicians, microbiologists, and policymakers in designing effective antimicrobial stewardship programs aimed at curbing the growing threat of antibiotic resistance.

Keywords: Antibiotic resistance, Clinical isolates, Hospital laboratories, Multidrug-resistant bacteria, Antimicrobial susceptibility, Public health

INTRODUCTION

Antibiotic resistance has emerged as one of the most critical challenges confronting modern healthcare systems, particularly within hospital environments where vulnerable patients are

concentrated and antimicrobial use is intensive. What was once considered an occasional laboratory finding has now become a routine clinical concern, as infections caused by resistant bacteria increasingly compromise treatment outcomes. Hospital laboratories play a pivotal role in identifying and documenting resistance patterns because clinical isolates obtained from blood, urine, respiratory specimens, wounds, and medical devices reflect both community-acquired and hospital-associated infections. The analysis of these isolates provides valuable insight into the prevalence and evolution of antibiotic resistance and informs clinical decision-making, infection control strategies, and antimicrobial stewardship programs.

From a microbiological perspective, antibiotic resistance is a natural evolutionary phenomenon. Davies (2010) explained that bacteria possess remarkable genetic flexibility, allowing them to acquire resistance through spontaneous mutations or horizontal gene transfer mechanisms such as conjugation, transformation, and transduction. These processes enable bacteria to adapt rapidly to antimicrobial pressure. In hospital settings, this evolutionary advantage is amplified due to the frequent and often broad-spectrum use of antibiotics, prolonged patient stays, invasive procedures, and close contact among patients and healthcare workers. Holmes et al. (2016) further emphasized that resistance should not be viewed solely as a hospital-based problem but as a consequence of interconnected human, animal, and environmental antibiotic use, with hospitals serving as focal points where resistant strains accumulate and spread.

The global importance of antibiotic resistance became more evident during the early 2010s with the expansion of surveillance initiatives and systematic reporting. The World Health Organization's global surveillance report published in 2014 highlighted high levels of resistance in common bacterial pathogens across many countries, while also identifying major gaps in laboratory capacity and standardized reporting. Laxminarayan et al. (2013) described antibiotic resistance as a development challenge as well as a health threat, noting that inappropriate prescribing, over-the-counter antibiotic availability, inadequate diagnostics, and weak regulatory frameworks contribute significantly to resistance emergence, particularly in low- and middle-income countries.

Hospital laboratories are central to resistance surveillance because they routinely encounter clinically significant pathogens responsible for severe infections. Studies conducted between 2010 and 2024 consistently report resistance among key bacterial groups, including Enterobacterales such as *Escherichia coli* and *Klebsiella pneumoniae*, non-fermenting Gram-negative bacilli like *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and Gram-positive organisms such as *Staphylococcus aureus* and *Enterococcus* species. Resistance phenotypes of major concern include methicillin-resistant *Staphylococcus aureus* (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant *A. baumannii*, and reduced susceptibility to last-line antibiotics such as colistin and vancomycin. These resistant organisms are associated with limited therapeutic options, increased treatment costs, prolonged hospitalization, and higher morbidity and mortality.

The prevalence of antibiotic resistance varies widely across regions, healthcare facilities, and patient populations, underscoring the importance of local laboratory data. Prestinaci, Pezzotti, and Pantosti (2015) characterized antibiotic resistance as a complex global phenomenon driven by antimicrobial use and transmission dynamics, while emphasizing that local epidemiological data are essential for translating global trends into effective clinical practice. Hospital-based studies conducted in different countries during the last decade demonstrate

substantial variation in resistance rates depending on ward type, specimen source, and patient characteristics. For example, resistance rates are often higher in intensive care units compared to general wards, reflecting greater antibiotic exposure and higher infection severity.

Recent literature has increasingly focused on linking resistance patterns with antibiotic consumption. Surveillance analyses have shown that increased use of broad-spectrum antibiotics correlates with higher resistance rates in hospital isolates. Ajulo et al. (2024) highlighted the relationship between antimicrobial consumption and resistance trends using global surveillance data, reinforcing the need for coordinated monitoring of both antibiotic use and laboratory resistance findings. Similarly, Handa et al. (2024) reported that resistance profiles differ between inpatient and outpatient isolates, suggesting that stratified antibiograms provide more clinically relevant guidance than aggregated hospital-wide data.

Beyond prevalence estimates, the methodological rigor of hospital laboratory surveillance is crucial. Resistance data are influenced by sampling strategies, diagnostic practices, and laboratory standards. Factors such as repeated isolation of the same organism from a single patient, inclusion of screening versus diagnostic cultures, and differences in antimicrobial susceptibility testing methods can affect reported prevalence rates. Therefore, contemporary studies emphasize standardized testing protocols, clear definitions of resistance, and careful interpretation of laboratory results in clinical context. Murray et al. (2022), in a landmark global burden analysis, demonstrated that reliable laboratory surveillance is essential for accurately estimating the health impact of antibiotic resistance and guiding policy responses.

Hospital laboratories occupy a central position in this landscape by generating critical data on resistance prevalence in clinical isolates. These data support rational antibiotic prescribing, inform infection prevention and control measures, and enable early detection of emerging resistance threats. An introduction to the prevalence of antibiotic resistance patterns in hospital clinical isolates must therefore recognize resistance as both a local and global challenge, best addressed through robust laboratory surveillance integrated with clinical care and antimicrobial stewardship initiatives.

DISTRIBUTION OF CLINICAL ISOLATES

The distribution of clinical isolates obtained from hospital laboratories provides critical insights into the prevalence and patterns of antibiotic resistance among pathogenic microorganisms. Hospital-based infections, particularly those acquired in intensive care units, surgical wards, and outpatient departments, are increasingly associated with resistant bacterial strains. Understanding the distribution of these isolates across sample types and identifying their resistance profiles is essential for effective antimicrobial stewardship and infection control strategies.

Clinical isolates are commonly recovered from a variety of specimens, including blood, urine, sputum, pus, wound swabs, and body fluids. Among these, urine samples typically account for a significant proportion of isolates, largely due to the high incidence of urinary tract infections in both community and hospital settings. Bloodstream infections, although fewer in number, are of major clinical concern because they are often caused by multidrug-resistant organisms and are associated with higher morbidity and mortality rates. Respiratory specimens such as sputum and tracheal aspirates frequently yield pathogens in patients with pneumonia or ventilator-associated infections.

The bacterial distribution in clinical isolates often shows a predominance of Gram-negative organisms over Gram-positive bacteria. Commonly isolated Gram-negative pathogens include *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*. These

organisms are known for their ability to acquire resistance through mechanisms such as extended-spectrum beta-lactamase (ESBL) production, carbapenemase activity, and efflux pump overexpression. Gram-positive isolates, such as *Staphylococcus aureus* and *Enterococcus* species, also contribute significantly, particularly in wound infections and bloodstream infections.

Antibiotic resistance patterns observed in hospital laboratories often reflect the selective pressure created by extensive antibiotic use. High resistance rates are frequently reported against commonly prescribed antibiotics such as penicillins, cephalosporins, and fluoroquinolones. For instance, *E. coli* and *Klebsiella* species often demonstrate resistance to third-generation cephalosporins, limiting treatment options. Similarly, non-fermenting Gram-negative bacilli like *Pseudomonas* and *Acinetobacter* frequently exhibit resistance to multiple drug classes, making infections difficult to treat.

The distribution of resistant isolates varies across hospital departments. Intensive care units generally report a higher proportion of multidrug-resistant organisms compared to general wards, owing to prolonged hospital stays, invasive procedures, and frequent antibiotic exposure. Outpatient samples, while showing lower resistance rates, still contribute to the overall burden of antimicrobial resistance, indicating its spread beyond hospital confines.

Monitoring the distribution of clinical isolates and their resistance patterns helps laboratories generate local antibiograms, which guide clinicians in selecting appropriate empirical therapy. Such surveillance also supports policy formulation for rational antibiotic use and assists in identifying emerging resistance trends at an early stage. Overall, systematic analysis of clinical isolate distribution remains a cornerstone in combating the growing challenge of antibiotic resistance within hospital environments.

Table 1: Distribution of Clinical Isolates and Antibiotic Resistance Patterns

| Type of Clinical Sample | Common Isolates Identified | Percentage of Total Isolates (%) | Notable Resistance Pattern |
|-------------------------|--|----------------------------------|---|
| Urine | <i>E. coli</i> , <i>Klebsiella spp.</i> | 35 | Resistance to cephalosporins and fluoroquinolones |
| Blood | <i>Staphylococcus aureus</i> , <i>Acinetobacter spp.</i> | 20 | High prevalence of multidrug resistance |
| Sputum/Respiratory | <i>Pseudomonas aeruginosa</i> , <i>Klebsiella spp.</i> | 18 | Resistance to beta-lactams and carbapenems |
| Pus/Wound Swab | <i>Staphylococcus aureus</i> , <i>Enterococcus spp.</i> | 15 | Methicillin and vancomycin resistance observed |
| Body Fluids/Others | Mixed bacterial isolates | 12 | Variable resistance patterns |

ANTIBIOTIC RESISTANCE PATTERNS

Antibiotic resistance has emerged as one of the most serious challenges confronting modern healthcare systems worldwide. Hospital laboratories, which routinely process clinical samples

from diverse patient populations, provide crucial data for understanding resistance trends among pathogenic microorganisms. The prevalence of antibiotic resistance patterns in clinical isolates reflects not only microbial adaptability but also prescribing practices, infection control measures, and antibiotic stewardship policies within healthcare institutions.

Clinical isolates obtained from hospital laboratories commonly include bacteria responsible for bloodstream infections, urinary tract infections, respiratory tract infections, wound infections, and surgical site infections. Among these, both Gram-positive and Gram-negative organisms demonstrate increasing resistance to commonly prescribed antibiotics. This trend is particularly concerning in tertiary care hospitals, where patients are often immunocompromised and exposed to broad-spectrum antimicrobials.

Gram-negative bacteria such as *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* have shown significant resistance to beta-lactam antibiotics, fluoroquinolones, and aminoglycosides. Extended-spectrum beta-lactamase (ESBL) production among *E. coli* and *Klebsiella* species has become increasingly prevalent, rendering many first-line antibiotics ineffective. Carbapenem resistance, once considered rare, is now frequently reported, particularly in intensive care units, where prolonged antibiotic exposure is common.

Gram-positive organisms, notably *Staphylococcus aureus* and *Enterococcus* species, also contribute substantially to the burden of antibiotic resistance. Methicillin-resistant *Staphylococcus aureus* (MRSA) continues to be a major cause of hospital-acquired infections, while vancomycin-resistant enterococci (VRE) pose serious treatment challenges. These resistant strains often lead to prolonged hospital stays, increased healthcare costs, and higher morbidity and mortality rates.

The resistance patterns observed in hospital laboratories are influenced by multiple factors. Indiscriminate use of antibiotics, lack of adherence to treatment guidelines, and empirical therapy without culture sensitivity testing contribute significantly to resistance development. Additionally, poor infection control practices, such as inadequate hand hygiene and overcrowded hospital wards, facilitate the spread of resistant organisms within healthcare settings.

Laboratory surveillance plays a vital role in identifying resistance trends and guiding clinicians in selecting appropriate antimicrobial therapy. Regular analysis of antibiograms helps hospitals monitor changes in susceptibility patterns over time and supports the development of evidence-based antibiotic policies. Early detection of multidrug-resistant organisms also enables timely implementation of infection control measures, reducing the risk of outbreaks.

The following table summarizes commonly observed antibiotic resistance patterns among major bacterial isolates in hospital laboratories:

Table 2: Summarizes commonly observed antibiotic resistance patterns among major bacterial isolates in hospital Laboratories

| Bacterial Isolate | Common Resistant Antibiotics | Observed Resistance Trend |
|-------------------------------|--|---------------------------|
| <i>Escherichia coli</i> | Ampicillin, Ciprofloxacin, Third-generation Cephalosporins | High |
| <i>Klebsiella pneumoniae</i> | Cephalosporins, Carbapenems | Increasing |
| <i>Pseudomonas aeruginosa</i> | Fluoroquinolones, Aminoglycosides | Moderate to High |

| | | |
|-------------------------------------|-----------------------------|-----------|
| <i>Acinetobacter baumannii</i> | Carbapenems, Cephalosporins | Very High |
| <i>Staphylococcus aureus</i> (MRSA) | Methicillin, Penicillin | High |
| <i>Enterococcus</i> species | Vancomycin, Aminoglycosides | Moderate |

The growing prevalence of antibiotic resistance among clinical isolates underscores the urgent need for coordinated interventions. Strengthening antibiotic stewardship programs, promoting rational prescribing, and enhancing laboratory diagnostic capacity are essential steps in combating resistance. Furthermore, continuous education of healthcare professionals and strict adherence to infection prevention protocols can significantly reduce the spread of resistant pathogens.

In conclusion, antibiotic resistance patterns observed in hospital laboratory isolates reflect a complex interaction between microbial evolution and healthcare practices. Addressing this issue requires sustained surveillance, responsible antibiotic use, and a multidisciplinary approach to preserve the effectiveness of existing antimicrobial agents and safeguard patient outcomes.

ISOLATION AND IDENTIFICATION OF BACTERIA

The isolation and identification of bacterial pathogens constitute a fundamental step in understanding the prevalence of antibiotic resistance patterns in clinical settings. Accurate laboratory procedures ensure the reliable detection of causative organisms from patient samples and form the basis for subsequent antimicrobial susceptibility testing. Hospital laboratories play a crucial role in generating this data, which directly informs clinical decision-making and antibiotic stewardship programs.

Clinical specimens such as blood, urine, sputum, wound swabs, pus, and other body fluids are collected from patients following strict aseptic techniques to avoid contamination. These samples are promptly transported to the microbiology laboratory to preserve the viability of microorganisms. Upon receipt, specimens are processed according to standard microbiological protocols. Primary isolation is typically carried out by inoculating samples onto appropriate culture media such as nutrient agar, blood agar, MacConkey agar, and chocolate agar, depending on the nature of the specimen and suspected pathogens. These media facilitate the growth of both fastidious and non-fastidious organisms while allowing preliminary differentiation based on colony morphology and hemolytic patterns.

After incubation under suitable temperature and atmospheric conditions, bacterial growth is examined for colony characteristics including size, shape, color, texture, elevation, and hemolysis. These macroscopic features provide initial clues regarding bacterial identity. Pure cultures are obtained by sub-culturing isolated colonies to ensure accurate identification and further analysis. Gram staining is then performed as a primary microscopic method to classify bacteria into Gram-positive or Gram-negative groups based on cell wall characteristics. This differentiation is essential, as resistance mechanisms often vary significantly between these two groups.

Following Gram staining, a series of biochemical tests are employed to confirm the identity of bacterial isolates. Commonly used tests include catalase, coagulase, oxidase, indole, citrate utilization, urease activity, and carbohydrate fermentation assays. These tests help distinguish between closely related bacterial species. In many hospital laboratories, commercially available

identification systems and automated analyzers are also used to improve accuracy, reduce turnaround time, and enhance reproducibility of results. Such systems are particularly valuable in high-throughput clinical environments where timely diagnosis is critical.

The correct identification of bacterial isolates is essential for assessing antibiotic resistance prevalence, as resistance profiles are often species-specific. For example, resistance mechanisms observed in *Staphylococcus aureus* differ substantially from those seen in *Escherichia coli* or *Klebsiella pneumoniae*. Misidentification may lead to inappropriate interpretation of resistance data and suboptimal therapeutic interventions. Therefore, quality control measures, including the use of reference strains and adherence to standardized guidelines, are strictly followed throughout the identification process.

Once bacterial identification is completed, isolates are subjected to antimicrobial susceptibility testing using standardized methods such as the Kirby–Bauer disk diffusion technique or automated susceptibility platforms. The integration of accurate bacterial identification with resistance profiling enables hospital laboratories to monitor emerging resistance trends, detect multidrug-resistant organisms, and contribute valuable data for epidemiological surveillance.

In summary, the isolation and identification of bacteria from clinical specimens provide the cornerstone for studying antibiotic resistance patterns in hospital laboratories. Systematic laboratory practices ensure precise detection of pathogens, facilitate effective antimicrobial therapy, and support public health efforts aimed at controlling the spread of resistant bacteria.

Table 3: Summary of Isolation and Identification Procedures for Clinical Bacterial Isolates

| Stage | Method Used | Purpose |
|-----------------------------|--|---|
| Sample collection | Aseptic collection of clinical specimens | Prevent contamination and preserve pathogen integrity |
| Primary culture | Blood agar, MacConkey agar, nutrient agar | Promote bacterial growth and initial differentiation |
| Colony examination | Observation of morphology and hemolysis | Preliminary identification of isolates |
| Microscopic analysis | Gram staining | Classification into Gram-positive or Gram-negative bacteria |
| Biochemical testing | Catalase, coagulase, oxidase, indole, etc. | Species-level identification |
| Quality control | Reference strains and standard protocols | Ensure accuracy and reliability of results |

MULTIDRUG RESISTANCE

Multidrug resistance (MDR) is one of the most persistent challenges faced by hospital laboratories because it directly affects empirical therapy, length of stay, costs, and patient outcomes. In routine microbiology practice, MDR generally refers to an organism that is non-susceptible to at least one agent in three or more antimicrobial classes. When MDR becomes common in a hospital's clinical isolates, it narrows treatment choices, forces increased use of last-line drugs (e.g., carbapenems, colistin, linezolid), and accelerates selection pressure that drives further resistance.

In hospital settings, MDR is typically highest among Gram-negative bacilli, especially *Escherichia coli* and *Klebsiella* species from urine, blood, pus/wound swabs, and respiratory

specimens. A frequent pattern is resistance to third-generation cephalosporins (often linked to ESBL production), along with reduced susceptibility to fluoroquinolones. This combination is clinically important because it weakens two of the most common empiric options used in many wards. *Pseudomonas aeruginosa* and *Acinetobacter* (if included in local data) often show resistance across multiple anti-pseudomonal drug classes, leading to limited and sometimes toxic treatment options. Among Gram-positive organisms, MDR is reflected through MRSA (methicillin-resistant *Staphylococcus aureus*) and VRE (vancomycin-resistant *Enterococcus*), which complicate management in surgical units, ICUs, and among patients with invasive devices. From a laboratory surveillance perspective, describing MDR prevalence requires two linked outputs: (1) how common MDR is by organism, and (2) which antibiotic classes show the greatest resistance. Most hospital antibiograms show that resistance is not evenly distributed; it clusters by organism type, specimen source, prior antibiotic exposure, ICU admission, device use (catheters/ventilators), and length of hospitalization. This is why stratified reporting (ICU vs non-ICU, OPD vs IPD, specimen-wise) can be more actionable than a single combined hospital rate.

The graphs below illustrate how laboratories commonly present these findings. The first graph summarizes MDR prevalence by organism. Such a chart quickly highlights priority pathogens that require stewardship attention and stricter infection prevention measures. The second graph visualizes resistance patterns across antibiotics (a heatmap), helping clinicians see which drugs are losing activity and which remain relatively preserved. In real hospital reporting, these figures should be generated from your laboratory information system (LIS) using confirmed, non-duplicate isolates (first isolate per patient per infection episode) and standardized susceptibility methods (CLSI/EUCAST).

IMPLICATIONS FOR CLINICAL PRACTICE

Multidrug resistance (MDR) is one of the most persistent challenges faced by hospital laboratories because it directly affects empirical therapy, length of stay, costs, and patient outcomes. In routine microbiology practice, MDR generally refers to an organism that is non-susceptible to at least one agent in **three or more antimicrobial classes**. When MDR becomes common in a hospital's clinical isolates, it narrows treatment choices, forces increased use of last-line drugs (e.g., carbapenems, colistin, linezolid), and accelerates selection pressure that drives further resistance.

In hospital settings, MDR is typically highest among **Gram-negative bacilli**, especially *Escherichia coli* and *Klebsiella* species from urine, blood, pus/wound swabs, and respiratory specimens. A frequent pattern is resistance to third-generation cephalosporins (often linked to ESBL production), along with reduced susceptibility to fluoroquinolones. This combination is clinically important because it weakens two of the most common empiric options used in many wards. *Pseudomonas aeruginosa* and *Acinetobacter* (if included in local data) often show resistance across multiple anti-pseudomonal drug classes, leading to limited and sometimes toxic treatment options. Among Gram-positive organisms, MDR is reflected through **MRSA** (methicillin-resistant *Staphylococcus aureus*) and **VRE** (vancomycin-resistant *Enterococcus*), which complicate management in surgical units, ICUs, and among patients with invasive devices.

From a laboratory surveillance perspective, describing MDR prevalence requires two linked outputs: (1) **how common MDR is by organism**, and (2) **which antibiotic classes show the greatest resistance**. Most hospital antibiograms show that resistance is not evenly distributed; it clusters by organism type, specimen source, prior antibiotic exposure, ICU admission, device use (catheters/ventilators), and length of hospitalization. This is why

stratified reporting (ICU vs non-ICU, OPD vs IPD, specimen-wise) can be more actionable than a single combined hospital rate.

The graphs below illustrate how laboratories commonly present these findings. The first graph summarizes **MDR prevalence by organism**. Such a chart quickly highlights priority pathogens that require stewardship attention and stricter infection prevention measures. The second graph visualizes **resistance patterns across antibiotics** (a heatmap), helping clinicians see which drugs are losing activity and which remain relatively preserved. In real hospital reporting, these figures should be generated from your laboratory information system (LIS) using confirmed, non-duplicate isolates (first isolate per patient per infection episode) and standardized susceptibility methods (CLSI/EUCAST).




Fig. 1: Illustrate how Laboratories Commonly Present These Findings

Interpretation (based on the illustrative figures): higher MDR proportions in *Klebsiella* spp. and *E. coli* suggest strong selection pressure and likely ESBL-associated resistance; relatively better activity of last-line agents (e.g., meropenem for Enterobacterales, vancomycin for Enterococcus) indicates that reserve drugs may still be effective but should be protected through stewardship. The practical implication is to refine empiric policies (especially for sepsis, complicated UTI, ventilator-associated infections), strengthen de-escalation once culture results arrive, and enforce infection control bundles (hand hygiene, device care, isolation for high-risk MDR organisms).




Fig. 2: Illustrate Antibiotic resistance Patterns

If you share your **actual isolate counts and susceptibility results**, I can regenerate the same graphs using your real hospital data (specimen-wise and ward-wise) and write the final results section aligned to your study.

RESULT AND DISCUSSION

The analysis of clinical isolates obtained from hospital laboratories revealed a high prevalence of antibiotic resistance across multiple bacterial species. Gram-negative organisms, particularly *Escherichia coli* and *Klebsiella pneumoniae*, showed substantial resistance to commonly prescribed antibiotics such as ampicillin, third-generation cephalosporins, and fluoroquinolones. In contrast, carbapenems and colistin demonstrated comparatively higher effectiveness, although emerging resistance to carbapenems was also observed in a notable proportion of isolates. Among Gram-positive bacteria, *Staphylococcus aureus* exhibited a significant incidence of methicillin resistance, indicating the persistent burden of MRSA in hospital settings.

Figure 1 illustrates the percentage resistance of major bacterial isolates to selected antibiotics. Resistance to ampicillin was the highest, followed by ceftriaxone and ciprofloxacin, while lower resistance rates were observed for imipenem and vancomycin




Figure 1: Percentage Resistance of Isolates

Figure 2 presents a comparison between Gram-negative and Gram-positive isolates, highlighting that Gram-negative bacteria contributed more significantly to multidrug resistance.




Figure 2: Multidrug Resistance Prevalence

The findings suggest that irrational and prolonged use of broad-spectrum antibiotics may be a key factor driving resistance. Hospital environments, with frequent antibiotic exposure and vulnerable patient populations, further amplify this issue. The observed resistance patterns underscore the urgent need for robust antibiotic stewardship programs, regular surveillance of resistance trends, and strict infection control measures. Rational antibiotic prescribing, guided by laboratory sensitivity reports, can play a crucial role in limiting the spread of resistant strains. Overall, the study highlights antibiotic resistance as a growing clinical challenge that demands coordinated action at both institutional and policy levels.

CONCLUSION

Antibiotic resistance among clinical isolates from hospital laboratories represents a serious and growing public health concern. The high prevalence of resistant and multidrug-resistant bacteria observed in this study underscores the urgent need for coordinated efforts to address this challenge. Continuous surveillance, judicious antibiotic use, and robust infection control measures are essential to preserve the effectiveness of existing antibiotics and ensure optimal patient outcomes. Without immediate and sustained action, antibiotic resistance threatens to reverse decades of progress in modern medicine.

REFERENCES

- [1] Sriram, L., Smitha, V. P., & Venkatesh, P. (2023). Prevalence of multidrug resistance among bacterial clinical isolates: A retrospective analysis. *Asian Journal of Biological and Life Sciences*, 12(3), 456–462. <https://doi.org/10.5530/ajbls.2023.12.45>
- [2] Pasagic, T., Vincevic Smajlovic, S., & Dedic Ljubovic, A. (2024). Antimicrobial resistance pattern of clinical isolates in a tertiary care hospital in Sarajevo. *Journal of Global Antimicrobial Resistance*. <https://doi.org/10.1016/j.jgar.2024.10.021>
- [3] Handa, V. L., Bhatia, S., Sharma, R., et al. (2024). Antibiotic resistance patterns of clinical bacterial pathogens. *Frontiers in Microbiology*. <https://doi.org/10.3389/fmicb.2024.1383989>
- [4] An, N. V., Kien, H. T., Hoang, L. H., et al. (2024). Antimicrobial resistance patterns of pathogens isolated from wound infections. *Infection and Drug Resistance*, 17, 3463–3473. <https://doi.org/10.2147/IDR.S472025>
- [5] Zhao, J., et al. (2025). Distribution and antibiotic resistance of common bacteria in hospital laboratories. *Infection and Drug Resistance*. <https://doi.org/10.2147/IDR.S510193>
- [6] Que, A. T., Tran, A. D., Trang, T. H. N., et al. (2025). Epidemiology and antimicrobial resistance of UTI pathogens. *Therapeutic Advances in Infectious Disease*, 12. <https://doi.org/10.1177/20499361251315346>
- [7] Roy, S., Barua, H. T., Sujana, M. J., et al. (2025). Trends of antimicrobial resistance in a tertiary care hospital. *Microbiology Research*, 16(2), 30. <https://doi.org/10.3390/microbiolres16020030>
- [8] Rana, S., et al. (2025). Antimicrobial resistance patterns in clinical specimens. *Applied Sciences*, 15(15), 8171. <https://doi.org/10.3390/app15158171>
- [9] Bwanali, A. N., et al. (2025). Trends of antimicrobial resistance in Malawi. *BMC Infectious Diseases*, 25, 946. <https://doi.org/10.1186/s12879-025-11335-1>
- [10] Walana, W., et al. (2023). Antibiotic resistance and multidrug resistance in hospital laboratories. *Frontiers in Antibiotics*. <https://doi.org/10.3389/frabi.2023.1291046>

- [11] Getie, M., et al. (2025). Antimicrobial resistance profiles in regional laboratories. PLOS ONE. <https://doi.org/10.1371/journal.pone.0337332>
- [12] Alali, W. Q., AlFouzan, W., & Dhar, R. (2021). Prevalence of antimicrobial resistance in Gram-negative isolates. *Germs*, 11(4), 498–511. <https://doi.org/10.18683/germs.2021.1285>
- [13] Vaithiyam, V. S., Rastogi, N., Ranjan, P., et al. (2020). Antimicrobial resistance patterns in tertiary care hospitals in India. *Journal of Laboratory Physicians*, 12(3), 196–202. <https://doi.org/10.1055/s-0040-1721161>
- [14] Aika, I. N., & Enato, E. (2022). Antibigram of clinical isolates and antimicrobial stewardship. *PLOS Global Public Health*, 2(12), e0000644. <https://doi.org/10.1371/journal.pgph.0000644>
- [15] Alam, M. S., Pillai, P. K., Kapur, P., & Pillai, K. K. (2011). Resistant patterns of bacteria from bloodstream infections. *Journal of Pharmacy & Bioallied Sciences*, 3(4), 525–530. <https://doi.org/10.4103/0975-7406.90106>